Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 2/2011

01-02-2011

The eighth American college of chest physicians guidelines on venous thromboembolism prevention: implications for hospital prophylaxis strategies

Authors: Michael H. Huo, Alex C. Spyropoulos

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2011

Login to get access

Abstract

Venous thromboembolism (VTE) is the most common potentially preventable form of hospital-related mortality. It presents as a major healthcare burden, affecting both medical and surgical patients. The prevention of VTE has been identified as one of the most important in-hospital safety practices in the US. VTE guideline recommendations provide a framework for clinical practice and guide VTE prophylaxis policies. Guidelines produced by the American College of Chest Physicians (ACCP) are considered to be the ‘gold standard’ in VTE prevention, diagnosis and management, and have been updated. A number of differences exist between the new 2008 ACCP guidelines on VTE prevention and the previous version published in 2004. There are variations regarding VTE prevention, including new and stronger evidence-based recommendations for several indications and agents. The updated guidelines give a strong recommendation that every hospital develop a VTE prevention policy, which is particularly important given the current international drive to reduce the incidence of VTE. A formal hospital policy should help improve compliance with appropriate VTE prophylaxis strategies. The ACCP guidelines form a basis for improving patient safety at a time of public reporting of quality of care, hospital accreditation, national standards of care, and pay for performance initiatives. In this review, changes in recommendations for VTE prevention in the 2008 ACCP guidelines compared with the previous edition in 2004 are outlined. In addition, outstanding areas of debate are discussed and the role of the 2008 ACCP guidelines in the context of the new VTE performance measures analyzed.
Literature
1.
go back to reference Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):381S–453SCrossRefPubMed Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):381S–453SCrossRefPubMed
2.
go back to reference Amin A, Stemkowski S, Lin J, Yang G (2007) Thromboprophylaxis rates in US medical centers, success or failure? J Thromb Haemost 5:1610–1616CrossRefPubMed Amin A, Stemkowski S, Lin J, Yang G (2007) Thromboprophylaxis rates in US medical centers, success or failure? J Thromb Haemost 5:1610–1616CrossRefPubMed
3.
go back to reference Amin AN, Stemkowski S, Lin J, Yang G (2008) Preventing venous thromboembolism in US hospitals: are surgical patients receiving appropriate prophylaxis? Thromb Haemost 99:796–797PubMed Amin AN, Stemkowski S, Lin J, Yang G (2008) Preventing venous thromboembolism in US hospitals: are surgical patients receiving appropriate prophylaxis? Thromb Haemost 99:796–797PubMed
4.
go back to reference Tapson VF, Decousus H, Pini M et al (2007) Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 132:936–945CrossRefPubMed Tapson VF, Decousus H, Pini M et al (2007) Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 132:936–945CrossRefPubMed
5.
go back to reference Cohen AT, Tapson VF, Bergmann JF et al (2008) Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371:387–394CrossRefPubMed Cohen AT, Tapson VF, Bergmann JF et al (2008) Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371:387–394CrossRefPubMed
6.
go back to reference Spyropoulos AC, Lin J (2007) Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 13:475–486PubMed Spyropoulos AC, Lin J (2007) Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 13:475–486PubMed
7.
go back to reference MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J (2006) Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm 63(20 Suppl 6):S5–S15CrossRefPubMed MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J (2006) Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm 63(20 Suppl 6):S5–S15CrossRefPubMed
8.
go back to reference Anderson FA Jr, Zayaruzny M, Heit JA, Fidan D, Cohen AT (2007) Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 82:777–782CrossRefPubMed Anderson FA Jr, Zayaruzny M, Heit JA, Fidan D, Cohen AT (2007) Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 82:777–782CrossRefPubMed
9.
go back to reference Nicolaides AN, Breddin HK, Fareed J et al (2001) Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 20:1–37CrossRefPubMed Nicolaides AN, Breddin HK, Fareed J et al (2001) Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 20:1–37CrossRefPubMed
11.
go back to reference Kahn SR, Panju A, Geerts W et al (2007) Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res 119:145–155CrossRefPubMed Kahn SR, Panju A, Geerts W et al (2007) Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res 119:145–155CrossRefPubMed
12.
go back to reference Burleigh E, Wang C, Foster D et al (2006) Thromboprophylaxis in medically ill patients at risk for venous thromboembolism. Am J Health Syst Pharm 63(20 Suppl 6):S23–S29CrossRefPubMed Burleigh E, Wang C, Foster D et al (2006) Thromboprophylaxis in medically ill patients at risk for venous thromboembolism. Am J Health Syst Pharm 63(20 Suppl 6):S23–S29CrossRefPubMed
13.
go back to reference Friedman RJ, Gallus AS, Cushner FD, Fitzgerald G, Anderson FA Jr, Global Orthopaedic Registry Investigators (2008) Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin 24:87–97PubMed Friedman RJ, Gallus AS, Cushner FD, Fitzgerald G, Anderson FA Jr, Global Orthopaedic Registry Investigators (2008) Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin 24:87–97PubMed
14.
go back to reference Lyman GH, Khorana AA, Falanga A et al (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490–5505CrossRefPubMed Lyman GH, Khorana AA, Falanga A et al (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490–5505CrossRefPubMed
15.
go back to reference Tooher R, Middleton P, Pham C et al (2005) A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals. Ann Surg 241:397–415CrossRefPubMed Tooher R, Middleton P, Pham C et al (2005) A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals. Ann Surg 241:397–415CrossRefPubMed
16.
go back to reference Durieux P, Nizard R, Ravaud P, Mounier N, Lepage E (2000) A clinical decision support system for prevention of venous thromboembolism: effect on physician behavior. JAMA 283:2816–2821CrossRefPubMed Durieux P, Nizard R, Ravaud P, Mounier N, Lepage E (2000) A clinical decision support system for prevention of venous thromboembolism: effect on physician behavior. JAMA 283:2816–2821CrossRefPubMed
17.
go back to reference Kucher N, Koo S, Quiroz R et al (2005) Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 352:969–977CrossRefPubMed Kucher N, Koo S, Quiroz R et al (2005) Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 352:969–977CrossRefPubMed
18.
go back to reference Mosen D, Elliott CG, Egger MJ et al (2004) The effect of a computerized reminder system on the prevention of postoperative venous thromboembolism. Chest 125:1635–1641CrossRefPubMed Mosen D, Elliott CG, Egger MJ et al (2004) The effect of a computerized reminder system on the prevention of postoperative venous thromboembolism. Chest 125:1635–1641CrossRefPubMed
19.
go back to reference Bauer JB, Chun DS, Karpinski TA (2008) Pharmacist-led program to improve venous thromboembolism prophylaxis in a community hospital. Am J Health Syst Pharm 65:1643–1647CrossRefPubMed Bauer JB, Chun DS, Karpinski TA (2008) Pharmacist-led program to improve venous thromboembolism prophylaxis in a community hospital. Am J Health Syst Pharm 65:1643–1647CrossRefPubMed
20.
go back to reference Mahan CE, Hussein MA, Amin AN, Spyropoulos AC (2009) Venous thromboembolism pharmacy intervention management program. J Thromb Haemost 7(Suppl 2). (abstract OC-TH-016) Mahan CE, Hussein MA, Amin AN, Spyropoulos AC (2009) Venous thromboembolism pharmacy intervention management program. J Thromb Haemost 7(Suppl 2). (abstract OC-TH-016)
21.
go back to reference Geerts WH, Pineo GF, Heit JA et al (2004) Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl):338S–400SCrossRefPubMed Geerts WH, Pineo GF, Heit JA et al (2004) Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl):338S–400SCrossRefPubMed
22.
go back to reference Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ (2007) Venous thromboembolism in the outpatient setting. Arch Intern Med 167:1471–1475CrossRefPubMed Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ (2007) Venous thromboembolism in the outpatient setting. Arch Intern Med 167:1471–1475CrossRefPubMed
23.
go back to reference Samama MM, Cohen AT, Darmon JY et al (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 341:793–800CrossRefPubMed Samama MM, Cohen AT, Darmon JY et al (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 341:793–800CrossRefPubMed
24.
go back to reference Leizorovicz A, Cohen AT, Turpie AG et al (2004) Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110:874–879CrossRefPubMed Leizorovicz A, Cohen AT, Turpie AG et al (2004) Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110:874–879CrossRefPubMed
25.
go back to reference Cohen AT, Davidson BL, Gallus AS et al (2006) Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332:325–329CrossRefPubMed Cohen AT, Davidson BL, Gallus AS et al (2006) Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332:325–329CrossRefPubMed
26.
go back to reference DeFrances CJ, Hall MJ (2007) 2005 National Hospital Discharge Survey. Adv Data 385:1–19PubMed DeFrances CJ, Hall MJ (2007) 2005 National Hospital Discharge Survey. Adv Data 385:1–19PubMed
27.
go back to reference Hull RD, Pineo GF (1999) Extended prophylaxis against venous thromboembolism following total hip and knee replacement. Haemostasis 29(Suppl S1):23–31PubMed Hull RD, Pineo GF (1999) Extended prophylaxis against venous thromboembolism following total hip and knee replacement. Haemostasis 29(Suppl S1):23–31PubMed
28.
go back to reference Eikelboom JW, Quinlan DJ, Douketis JD (2001) Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 358:9–15CrossRefPubMed Eikelboom JW, Quinlan DJ, Douketis JD (2001) Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 358:9–15CrossRefPubMed
29.
go back to reference Hull RD, Pineo GF, Stein PD et al (2001) Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 135:858–869PubMed Hull RD, Pineo GF, Stein PD et al (2001) Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 135:858–869PubMed
30.
go back to reference Rasmussen MS, Jorgensen LN, Wille-Jørgensen P et al (2006) Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 4:2384–2390CrossRefPubMed Rasmussen MS, Jorgensen LN, Wille-Jørgensen P et al (2006) Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 4:2384–2390CrossRefPubMed
31.
go back to reference Bergqvist D, Agnelli G, Cohen AT et al (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346:975–980CrossRefPubMed Bergqvist D, Agnelli G, Cohen AT et al (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346:975–980CrossRefPubMed
32.
go back to reference Eriksson BI, Lassen MR, PENTasaccharide in HIp-FRActure Surgery Plus Investigators (2003) Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 163:1337–1342CrossRefPubMed Eriksson BI, Lassen MR, PENTasaccharide in HIp-FRActure Surgery Plus Investigators (2003) Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 163:1337–1342CrossRefPubMed
33.
go back to reference Bottaro FJ, Elizondo MC, Doti C et al (2008) Efficacy of extended thrombo-prophylaxis in major abdominal surgery: what does the evidence show? A meta-analysis. Thromb Haemost 99:1104–1111PubMed Bottaro FJ, Elizondo MC, Doti C et al (2008) Efficacy of extended thrombo-prophylaxis in major abdominal surgery: what does the evidence show? A meta-analysis. Thromb Haemost 99:1104–1111PubMed
34.
go back to reference King CS, Holley AB, Jackson JL, Shorr AF, Moores LK (2007) Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: a metaanalysis. Chest 131:507–516CrossRefPubMed King CS, Holley AB, Jackson JL, Shorr AF, Moores LK (2007) Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: a metaanalysis. Chest 131:507–516CrossRefPubMed
35.
go back to reference Caprini JA, Arcelus JI, Reyna JJ (2001) Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol 38(2 Suppl 5):12–19CrossRefPubMed Caprini JA, Arcelus JI, Reyna JJ (2001) Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol 38(2 Suppl 5):12–19CrossRefPubMed
36.
go back to reference Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902–4907CrossRefPubMed Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902–4907CrossRefPubMed
37.
go back to reference Spyropoulos AC (2009) Upper vs lower extremity deep vein thrombosis: outcome definitions of venous thromboembolism for clinical predictor rules or risk factor analyses in hospitalized patients. J Thromb Haemost 7:1041–1042CrossRefPubMed Spyropoulos AC (2009) Upper vs lower extremity deep vein thrombosis: outcome definitions of venous thromboembolism for clinical predictor rules or risk factor analyses in hospitalized patients. J Thromb Haemost 7:1041–1042CrossRefPubMed
38.
go back to reference Kuderer NM, Khorana AA, Francis CW et al. (2008) Venous thromboembolism risk model predicts early progression and overall mortality in cancer patients receiving chemotherapy. Blood 112. (abstract 172) Kuderer NM, Khorana AA, Francis CW et al. (2008) Venous thromboembolism risk model predicts early progression and overall mortality in cancer patients receiving chemotherapy. Blood 112. (abstract 172)
39.
go back to reference Spyropoulos AC, Anderson FA, FitzGerald G, Decousus H, Tapson V (2009) Venous thromboembolism risk factors in acutely ill hospitalized medical patients: findings from the improve registry. J Thromb Haemost 7(Suppl 2). (abstract OC-MO-052) Spyropoulos AC, Anderson FA, FitzGerald G, Decousus H, Tapson V (2009) Venous thromboembolism risk factors in acutely ill hospitalized medical patients: findings from the improve registry. J Thromb Haemost 7(Suppl 2). (abstract OC-MO-052)
40.
go back to reference Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M, PEGASUS investigators (2005) Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 92:1212–1220CrossRefPubMed Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M, PEGASUS investigators (2005) Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 92:1212–1220CrossRefPubMed
41.
go back to reference Turpie AG, Bauer KA, Caprini JA et al (2007) Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for the prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. J Thromb Haemost 5:1854–1861CrossRefPubMed Turpie AG, Bauer KA, Caprini JA et al (2007) Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for the prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. J Thromb Haemost 5:1854–1861CrossRefPubMed
42.
go back to reference Levitan N, Dowlati A, Remick SC et al (1999) Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78:285–291CrossRef Levitan N, Dowlati A, Remick SC et al (1999) Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78:285–291CrossRef
43.
go back to reference Mukherjee D, Lidor AO, Chu KM, Gearhart SL, Haut ER, Chang DC (2008) Postoperative venous thromboembolism rates vary significantly after different types of major abdominal operations. J Gastrointest Surg 12:2015–2022CrossRefPubMed Mukherjee D, Lidor AO, Chu KM, Gearhart SL, Haut ER, Chang DC (2008) Postoperative venous thromboembolism rates vary significantly after different types of major abdominal operations. J Gastrointest Surg 12:2015–2022CrossRefPubMed
44.
go back to reference Ruíz-Giménez N, Suárez C, González R et al (2008) Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 100:26–31PubMed Ruíz-Giménez N, Suárez C, González R et al (2008) Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 100:26–31PubMed
45.
go back to reference Agnelli C, Gussoni G, Bianchini C, Verso M, Tonato M (2008) A randomized double-blind placebo-controlled study on nadroparin for prophylaxis of thromboembolic events in cancer patients receiving chemotherapy: the PROTECHT study. Blood 112. (abstract 6) Agnelli C, Gussoni G, Bianchini C, Verso M, Tonato M (2008) A randomized double-blind placebo-controlled study on nadroparin for prophylaxis of thromboembolic events in cancer patients receiving chemotherapy: the PROTECHT study. Blood 112. (abstract 6)
46.
go back to reference Weber DM, Chen C, Niesvizky R et al (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133–2142CrossRefPubMed Weber DM, Chen C, Niesvizky R et al (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133–2142CrossRefPubMed
49.
go back to reference Sobieraj-Teague M, Eikelboom JW, Hirsh J (2010) How can we reduce disagreement among guidelines for venous thromboembolism prevention? J Thromb Haemost 8(4):675–677CrossRefPubMed Sobieraj-Teague M, Eikelboom JW, Hirsh J (2010) How can we reduce disagreement among guidelines for venous thromboembolism prevention? J Thromb Haemost 8(4):675–677CrossRefPubMed
50.
go back to reference Eikelboom JW, Karthikeyan G, Fagel N, Hirsh J (2009) American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest 135:513–520CrossRefPubMed Eikelboom JW, Karthikeyan G, Fagel N, Hirsh J (2009) American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest 135:513–520CrossRefPubMed
52.
go back to reference Guyatt GH, Oxman AD, Kunz R et al (2008) Going from evidence to recommendations. BMJ 336:1049–1051CrossRefPubMed Guyatt GH, Oxman AD, Kunz R et al (2008) Going from evidence to recommendations. BMJ 336:1049–1051CrossRefPubMed
61.
go back to reference Vats V, Nutescu EA, Theobald JC, Wojtynek JE, Schumock GT (2007) Survey of hospitals for guidelines, policies, and protocols for anticoagulants. Am J Health Syst Pharm 64:1203–1208CrossRefPubMed Vats V, Nutescu EA, Theobald JC, Wojtynek JE, Schumock GT (2007) Survey of hospitals for guidelines, policies, and protocols for anticoagulants. Am J Health Syst Pharm 64:1203–1208CrossRefPubMed
Metadata
Title
The eighth American college of chest physicians guidelines on venous thromboembolism prevention: implications for hospital prophylaxis strategies
Authors
Michael H. Huo
Alex C. Spyropoulos
Publication date
01-02-2011
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2011
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-010-0500-6

Other articles of this Issue 2/2011

Journal of Thrombosis and Thrombolysis 2/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.